Preview

Качественная клиническая практика

Расширенный поиск

Нефротоксичность антибиотиков у новорожденных

Полный текст:

Аннотация

Применение антибактериальных препаратов является основной причиной возникновения заболеваний для всех возрастных групп. Повреждение почек происходит посредством двух основных механизмов, в частности напрямую и при помощи иммунологических медиаторов. Для некоторых антибиотиков (аминогликозиды и ванкомицин) нефротоксичностъ, обратимая после отмены препарата, является очень частым побочным эффектом, вплоть до возникновения острой почечной недостаточности, частота возникновения которой в настоящее время возрастает. Антибактериальные препараты очень часто используются в неонаталъном периоде, особенно у новорожденных с очень низкой массой тела при рождении.

Об авторе

Е. М. Лукьянова
Российский государственный медицинский университет, г. Москва
Россия


Список литературы

1. Joannides R., Dhib M., Filllastre J.P. Drug-induced nephropathies [in French]. Rev Prat 1992; (17):2210-6.

2. Khoory B.J., Fanos V., Dall'Agnola A., et al. Aminoglycosides, risk factors and neonatal kidney [in Italian]. Med Surg Ped 1996; 18: 495-9.

3. Pospishil Y.0., Antonovich M.A. Antibiotic associated nephropathy. Pol J Pathol 1996; 47 (1):13-7.

4. Fanos V., Benini D., Vinco S., et al. Glycopeptides and the neonatal kidney [in Italian]. Med Surg Ped 1997; 19:259-62.

5. Fanos V., Cataldi L. Aminoglycoside-induced nephrotoxicity in the newborn. In: Cataldu L, Fanos V, Simeoni U, editors. Neonatal nephrology in progress. Lecce: Agora, 1996; 1 S2-81.

6. Montini G., Barbieri P., Zaramella P., et al. Epidemiology of acute renal failure in the neonatal period [in Italian]. Ital J Pediatr 1995: 129-40.

7. Simeoni V., Matis J., MesserJ. Clinical implications of renal immaturity in tiny, premature infants. In: Cataldi VL, Fanos V, Simeoni U, editors. Neonatal nephrology in progress. Lecce: Agora,1996:129-40.

8. Verlato G., Fanos V., Tato I., et al. Mortality from renal diseases in the Italian population aged than 20 years in the period 1979-99 [in Italian]. Med Surg Ped 1997; 19 (5); 365-8.

9. Sereni F., Assael B.M., Mely M.L. Drugs, kidney, development [in Italian]. UP 1998; 14: 463-73.

10. Plebani M., Mussap M., Bertelli L., et al. Assessment ofcystatin С serum levels in healthy pregnant women and in their newboms respectively Med Surg Ped 1997; 19 (5): 325-30.

11. Mussap M., Plebani M., Fanos V., et al. Serum cystatin С in healthy full-term newborns: preliminary reference values for a promising endogenous marker of glomerular filtration rate. Prenat Neonat Med 1997; 2: 338-42.

12. Fanos V., Padovani E.M. Importance of evaluation of urinary enzymes and microglobulins in the neonatal period [in Italian] UP 1995; 6: 775-83.

13. Weber M.H., Verwiebe R. Alpha 1 microglobulin (protein HC): features of a promising indicator ofproximal tubular dysfunction. Eur J Clin Chem Clin Biochem 1992; 30: 683-91.

14. Padovani E.M., Fanos V., Mussap M., et al. Neonatal tubular proteinuria: normality values of urinary alpha-1 microglobulin [in Italian]. I J P 1992; 3 (18): 323-5.

15. Tsukahara H., Huraoka M., Kuriyami M., et al. Urinary Alpha 1 microglobulin as an index ofproximal tubular function in early infancy. Pediatr Nephrol 1993; 7: 199-201.

16. Smith G.C., Winterborn M.H., Taylor C.M., et al. Assessment of retinol-binding protein excretion in normal children. Pediatr Nephrol 1994; 8: 148-50.

17. Padovani E.M., Fanos V., Mussap M., et al. Enzyme and tubular protein contents in amniotic fluid. Eur J Obstet Gynecol Reprod Bio 1994; 55: 129-33.

18. Mussap M., Fanos V., Piccoli A., et al. Low molecular mass protein and urinary enzymes in amniotic fluid of healthy pregnant woman at progressive stages of gestation. Clin Biochem 1996, 1: 1-8.

19. Donaldson M.D.C., Chambers R.E., Woolridge W. Stability of alpha-1 microglobulin, beta-2 microglobulin and retinol-binding protein in urine. Clin Chim Acta 1992; 179; 73-8.

20. Gordjani N., Burghard R., Muller L., et al. Urinary excretion ofadenosine desaminase binding protein in neonates treated with tobramycin. Pediatr Nephrol 1995; 9: 419-22.

21. Price G. The role of NAG (N-acetyl-Beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 1992; 36 (1 Suppl.):14S-19S.

22. Mondorf A. W., Folkenberg F. W., Lindner A. Kidney tolerance of vancomycin: an update on the use of glycopeptides in the management of Gram positive infections. Macclesfield: Pennine Press, 1993: 10-5.

23. Tairu Т., Yoshimura A., Lizuka K., et al. Urinary epidermal growth factor levels in patients with acute renal failure. Am J Kidney Dis 1993; 22 (5): 656-61.

24. Saez-Llorens X., McCracken G.H. Clinical pharmacology of antibacterial agents. In: Remington JS, Klein JO, editors. Infectious disease of the fetus, newborns and infants. Philadelphia: W.B. Saunders, 1995: 1287-336.

25. Mussap M., Fanos V., Ruzzante N.. et al. Urinary N-acetyl-b-D-glucosaminidase (NAG) and alpha 1 microglobulin excretion as an index of renal tubular dysfunction in the neonate. Eur J Lab Med 1997; 5 (З): 1-4.

26. Borderon J.C., Longer J., Ramponi N., et al. Survey of antibiotic therapies in pediatric intensive care units [in French]. Ann Pediatr 1992; 39; 27-36.

27. Marra F., Partovi N., Jewerson P. Aminoglycoside administration as a single daily dose: an improvement to current practice or a repeat of previous errors? Drugs 1996; 52 (З): 344-70

28. Moestrup S., Cm S., Varum C., et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995; 96: 1404-13.

29. Hock R., Anderson R.J. Prevention of drug-induced nephrotoxicity in the intensive care unit. J Crit Care 1995; 10 (I): 33-43.

30. Smaoui H., Schaeverbeke M., Mallie J.P., et al. Transplacental effects of gentamicin on endocytosis in rat renal proximal tubular cells. Pediatr Nephron 1994; 8 (4): 447-50.

31. Ibrahim S., Langhendries J.P., Bernard A. Urinary phospholipids excretion in neonates treated with amikacin. Int J Clin Pharmacol Res 1994; 14: 149-56.

32. Prins J.M., Buller H.R., Kuijper E.J., et al. Once versus thrice daily gentamicin in patients with serious infection. Lancet 1993; 341: 335-9.

33. Colding H., Brygge K., Brendstrup L., et al. Enzymuria in neonates receiving continuous intravenous infusion ofgentamicin. APMIS 1992; 100: 119-24.

34. Skopnik H., Wallraf R., Nies В., et al. Pharmacokinetics and antibacterial activity of daily gentamicin. Arch Dis Child 1992; 76: 57-61.

35. Sprintage J.E. Toxic nephropathies. Curr Opin Pediatr 1997; 9: 166-9.

36. Deamer R., Dial L. The evolution of aminoglycoside therapy: a single daily dose. Ann Fam Phys 1996; 53: 1782-6.

37. Hatala R., Dinh R., Cook D. Once daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717-24.

38. Lehly D.J., Braun B.I., Tholl D.A., et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy? J Am Soc Nephrol 1993; 4 (I): 81-90.

39. Roberts D.S., Haycock G.B., Da/ton R.N., et al. Prediction of acute renal failure afterbirth asphyxia. Arch Dis Child 199; 65: 1021-8.

40. Zager R.A. Endotoxemia, renal hypoperfusion and fever: interactive risk factors for aminoglycoside and sepsis-associated acute renal failure. Am J Kidney Dis 1992; XX: 223-30.

41. Giapros V.I., Andronikou S., Cholesas V.I., et al. Renal function in premature infants during aminoglycoside therapy. Pediatr Nephrol 1995; 9 (2): 163-6.

42. Suzuki Т., Togari H. Effect ofhypoxia on renal prostaglandins E2 production in human and rat neonates. Bio Neonate 1992; 62: 127-35.

43. Gouyon J.B., GuignardJ.P. Rein et diuretiques. Progres Neonat 1998; 8: 224-57.

44. Fanos V., Khoory B.J., Benini D., et al. Antibiotics nephropathy in the neonatal age [in Italian]. Doctor Pediatr 1997; 12 (б): 5-14.

45. Aujard Y. Neonatal infections - a special case? Res Clin Forums 1997; 19: 67-77.

46. Odio С. Sepsis in children - a therapeutic approach. Res Clin Forums 1997; 19; 31-40.

47. Rodvold K.A., Gentry С.A., Plank G.S., et al. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995; 17: 239-46.

48. Fanos V., Verlato G., Dal Moro A., et al. Staphylococcus epidermidis isolation and antibiotic resistance in the neonatal intensive care unit. J Chemother 1995; 7: 26-9.

49. Fanos V., Kacet N.. Mosconi G. A review of ticoplanin in the treatment if serious neonatal infections. Eur J Pediatr 1997; 156: 423-7.

50. Rodvold K.A., Everett J.A., Pruka R.D., et al. Pharmacokinetic and administration regimens of vancomycin in neonates, infants and children. Clin Pharmacokinet 1997; 33: 32-51.

51. Boussemart Т., Cardona J., Berthier M., et al. Cardiac arrest associated with vancomycin in a neonate [letter]. Arch Dis Child 1995; 73 (F Suppl.): 123S.

52. Beauchamp D., Gourge P., Simard M., et al. Subcellular localization of tobramycin and vancomycin given alone and in combination in proximal tubular cells, Determined by immunogold labeling. Antimicrob Agents Chemother 1992; 36 (10): 2204-10.

53. Fauconneau В., de Lemos E., Pariat С. Chrononephrotoxicity in rat of a vancomycin and gentamicin combination. Pharmacol Toxicol 1992; 71: 31-6.

54. Chow A. W., Azar R. W. Glycopeptides and nephrotoxicity Intensive Care Med 1994; 20: 523-9.

55. Philips G., Golledge C. Vancomycin and teicoplanin: something old, something new. Med J Aust 1992; 156: 53-7.

56. Cantu T.G., Yamanaka S., Yuen N.A., et al. Serum vancomycin concentrations: reapprisa; of their clinical value. Clin Infect Dis 1994; 18: 533-43.

57. Rybak M.J., Albrecht L.S., Boike S.C., et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. Antimicrob Chemother 1990; 25: 679-S7.

58. Borderon J.C., LaugierJ., Chamboux C., et al. Continuous Infusion ofvancomycin in newborn infants [in French]. Pathol Biol 1994; 42 (5); 525-9.

59. Saunders N.J. Why monitor peak vancomycin concentrations? Lancet 1995; 345: 645-6.

60. Ashbury W.H., Daisey E.H., Rose W.B., et al. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother 1993; 27: 490-8.

61. Wood Mj. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-22.

62. Contra Т. Teicoplanin/vancomycin: comparative studies in neutropenic patients [abstract] Can J Infect 1995; 6: 309C.

63. Kirschstein M., Jensen R., Nelskamp I., et al. Proteinuria in very low birth weight infants during teicoplanin and vancomycin prophylaxis of infection [abstract]. Pediatr Nephrol 1995; 9: 54C.

64. Degraeuwe P.L., Beuman G.H., van Triel F.H., et al. Use of teicoplanin in preterm neonates with staphylococcal late-onset neonatal sepsis. Biol Neonate 1998; 75 (З): 287-95.

65. MollerJ.C., Nelskamp I., Jensen R., et al. Teicoplanin pharmacology in prophylaxis for coagulase-negative staphylococcal sepsis of very low birth weight infants. Acta Pediatr 1996; 85: 638-40.

66. Fanos V., Mussap M., Khoory B.J., et al. Renal; tolerability of teicoplanin in a case of neonatal overdose. J Chemother 1998; 10 (5): 381-4.

67. Fekkety F.R. Safety of parenteral third generations cephalosporins. Am J Med 1990; 14: 616-52.

68. Cunha B.A. Third generation cepohalosporines: a review. Clin Ther 1992; 14: 616-52.

69. Типе В.М. Renal tubular transport and nephrotoxicity ofbeta-lactam antibiotic: structure-activity relationship. Miner Electrolyte Metab 1994; 20: 221-31.

70. Типе В.М. Nephrotoxicity ofbet-lactam antibiotics: mechanism and strategies for prevention. Pediatr Nephrol 1997; 11: 768-72.

71. Kaloyanides G.J. Antibiotic-related nephrotoxicity. Nephrol Dial Transplant 1994; 9 (4 Suppl.): 130S-4S.

72. Kasama R., Sorbello A. Renal and electrolyte complications associated with antibiotic therapy. Am Fam Physician 1996; 53 ;(1 Suppl.): 227S-32S.

73. Puthicheary S.D., Goldsworhty P.J. Ceftazidime and cefotaxime: the clinician's choice. Clin Ther 1984; 11 (2): 186-204.

74. Bradley J.S., Ching D.L.K., Wilson T.A., et al. Once daily ceftriaxon to complete therapy off uncomplicated Group В Streptococcal infection in the neonate / Clin Pediatr 1992 may, 274-8.

75. Dajani A.S. Cefotaxime-safety, spectrum and future prospects. Res Clin forums 1997; 19: 57-64.

76. Fanos V., Fostini R., Panebianco A. Ceftazidime in common pediatric infections: experience on 262 cases [in Italian] Clin Ther 1991; 13: 327-32.

77. Fanos V. Cephalosporins and the neonatal kidney. Proceedings of the 8th International Workshop on Neonatal Nephrology Fanos V, Fostini R. Cataldi L, Fanos V, editors. 1998 Apr 14; Rome. II Pediatra XX; 8 : 39-42.

78. Edwards M.S. Antimicrobial therapy in pregnancy and neonates. Clin Perinatol 1997; 24 (I): 91-105.

79. Fried Т. Acute interstitial nephritis: why do the kidneys fail? Postgrad Med 1993; 5: 105-20.

80. Kuigh M. Adverse drug reactions in neonates. J Clin Pharmacol 1994; 34 (2): 128-35.

81. Arrietta A. Use of meropenem in treatment of serious infections in children: review of current literature. Clin Infect Dis 1997; 24 Suppl. 2: 207S-12S.

82. Bradley J.S. Meropenem: a new extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics. Pediatr Infect Dis J 1997; 16: 263-8.

83. Lebel M.H., McCrackien G.H. Aztreonam: review of the clinical experience and potential uses in pediatrics. Pediatr Infect Dis J 1998; 7: 133-9.

84. Bosso J.A., Black P.G. The use of aztreonam in pediatric patients: a review. Pharmacotherapy 1991; 11: 20-5.

85. Cuzzolin L., Fanos V., Zambreri D., et al. Pharmacokinetics and renal tolerance ofaztreonam in premature infant


Для цитирования:


Лукьянова Е.М. Нефротоксичность антибиотиков у новорожденных. Качественная клиническая практика. 2002;(2):53-62.

For citation:


. . Kachestvennaya klinicheskaya praktika. 2002;(2):53-62. (In Russ.)

Просмотров: 45


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2588-0519 (Print)
ISSN 2618-8473 (Online)